Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CC-99712 |
| Synonyms | |
| Therapy Description |
CC-99712 is an antibody-drug conjugate (ADC) comprising an antibody that targets BCMA linked to a cytotoxic agent, potentially resulting in increased death of BCMA-expressing tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CC-99712 | CC99712|CC 99712 | TNFRSF17 Antibody 22 | CC-99712 is an antibody-drug conjugate (ADC) comprising an antibody that targets BCMA linked to a cytotoxic agent, potentially resulting in increased death of BCMA-expressing tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04036461 | Phase I | CC-99712 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | Terminated | USA | ITA | FRA | ESP | CAN | 0 |